These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 8122371)
21. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181 [TBL] [Abstract][Full Text] [Related]
22. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Huang X; Jin W; Hu K; Luo S; Du T; Griffin GE; Shattock RJ; Hu Q Virology; 2012 Feb; 423(1):97-106. PubMed ID: 22192629 [TBL] [Abstract][Full Text] [Related]
23. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. McKeating JA; Cordell J; Dean CJ; Balfe P Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382 [TBL] [Abstract][Full Text] [Related]
24. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies. Hemming A; Gram GJ; Bolmstedt A; Losman B; Hansen JE; Ricksten A; Olofsson S Arch Virol; 1996; 141(11):2139-51. PubMed ID: 8973529 [TBL] [Abstract][Full Text] [Related]
25. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. Botarelli P; Houlden BA; Haigwood NL; Servis C; Montagna D; Abrignani S J Immunol; 1991 Nov; 147(9):3128-32. PubMed ID: 1717587 [TBL] [Abstract][Full Text] [Related]
26. Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop. Hansen JE; Jansson B; Gram GJ; Clausen H; Nielsen JO; Olofsson S Arch Virol; 1996; 141(2):291-300. PubMed ID: 8634021 [TBL] [Abstract][Full Text] [Related]
27. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120. Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053 [TBL] [Abstract][Full Text] [Related]
28. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. Tilley SA; Honnen WJ; Racho ME; Chou TC; Pinter A AIDS Res Hum Retroviruses; 1992 Apr; 8(4):461-7. PubMed ID: 1376135 [TBL] [Abstract][Full Text] [Related]
29. The antigen/antibody specificity exchanger: a new peptide based tool for re-directing antibodies of other specificities to recognize the V3 domain of HIV-1 gp120. Sällberg M; Sherefa K; Zhang ZX Biochem Biophys Res Commun; 1994 Dec; 205(2):1386-90. PubMed ID: 7802674 [TBL] [Abstract][Full Text] [Related]
30. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. Gray ES; Moore PL; Pantophlet RA; Morris L J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239 [TBL] [Abstract][Full Text] [Related]
31. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp 120: identification of a very early fusion-independent event as a neutralization target. Armstrong SJ; Dimmock NJ J Gen Virol; 1996 Jul; 77 ( Pt 7)():1397-402. PubMed ID: 8757979 [TBL] [Abstract][Full Text] [Related]
32. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Schønning K; Jansson B; Olofsson S; Nielsen JO; Hansen JS Virology; 1996 Apr; 218(1):134-40. PubMed ID: 8615015 [TBL] [Abstract][Full Text] [Related]
33. Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1. Hioe CE; Hildreth JE; Zolla-Pazner S AIDS Res Hum Retroviruses; 1999 Apr; 15(6):523-31. PubMed ID: 10221529 [TBL] [Abstract][Full Text] [Related]
34. Construction of reshaped human antibodies with HIV-neutralizing activity. Maeda H; Matsushita S; Eda Y; Kimachi K; Tokiyoshi S; Bendig MM Hum Antibodies Hybridomas; 1991 Jul; 2(3):124-34. PubMed ID: 1873503 [TBL] [Abstract][Full Text] [Related]
35. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. Back NK; Smit L; Schutten M; Nara PL; Tersmette M; Goudsmit J J Virol; 1993 Nov; 67(11):6897-902. PubMed ID: 8411395 [TBL] [Abstract][Full Text] [Related]
36. Alanine substitution of two arginines in amino terminus of V3 of SIV disrupts CD4 binding whereas a similar replacement of two amino acids, lysine and arginine, in the carboxyl half of V3 prevents binding of a neutralizing monoclonal antibody. Javaherian K; Zuchowski L; Clark FT AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1101-5. PubMed ID: 8554907 [TBL] [Abstract][Full Text] [Related]
37. Sulfated polyester interactions with the CD4 molecule and with the third variable loop domain (v3) of gp120 are chemically distinct. Lederman S; Bergmann JE; Cleary AM; Yellin MJ; Fusco PJ; Chess L AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1599-610. PubMed ID: 1457206 [TBL] [Abstract][Full Text] [Related]
38. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099 [TBL] [Abstract][Full Text] [Related]